<DOC>
	<DOCNO>NCT02023099</DOCNO>
	<brief_summary>This phase 3 , double-blinded , multicenter study . The study consist 2 substudies : Substudy 1 ( SS1 ) double-blinded enroll non-cirrhotic subject Substudy 2 ( SS2 ) open label enroll subject compensate cirrhosis .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCVinfection prior study enrollment Screening laboratory result indicate HCV subgenotype 1b infection Subject plasma HCV RNA level great 10,000 IU/mL Screening Voluntarily sign inform consent Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Coinfection Hepatitis B Virus ( HBV ) , human immunodeficiency virus ( HIV ) HCV genotype subgenotype 1b Prior therapy direct act antiviral agent treatment HCV , include telaprevir , simeprevir boceprevir Any cause liver disease chronic HCVinfection , include limited following : hemochromatosis ; alpha1 antitrypsin deficiency ; Wilson 's disease ; autoimmune hepatitis ; alcoholic liver disease ; drugrelated liver disease ; clinically significant laboratory abnormality ; uncontrolled clinically significant disease , disorder medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 1b</keyword>
	<keyword>Cirrhotic</keyword>
	<keyword>Treatment Experienced</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Japanese</keyword>
	<keyword>ombitasvir</keyword>
	<keyword>paritaprevir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>VIEKIRAX Combination Tablets</keyword>
</DOC>